Affinity Asset Advisors LLC grew its holdings in shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 16.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,284,512 shares of the biopharmaceutical company's stock after buying an additional 459,512 shares during the period. Affinity Asset Advisors LLC owned approximately 3.12% of ProQR Therapeutics worth $4,368,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Jane Street Group LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $30,000. Invesco Ltd. bought a new position in shares of ProQR Therapeutics in the 4th quarter worth $32,000. Alpine Global Management LLC bought a new position in shares of ProQR Therapeutics in the 4th quarter worth $39,000. Two Sigma Securities LLC purchased a new stake in ProQR Therapeutics in the 4th quarter valued at $40,000. Finally, Vontobel Holding Ltd. purchased a new stake in ProQR Therapeutics in the 1st quarter valued at $48,000. 32.65% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the company. Oppenheimer lowered their price target on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Evercore ISI reiterated an "outperform" rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. JMP Securities reiterated a "market outperform" rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Friday, June 27th. Chardan Capital reiterated a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, August 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Friday, June 27th. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $8.00.
Read Our Latest Analysis on PRQR
ProQR Therapeutics Stock Performance
Shares of PRQR traded up $0.06 during trading hours on Friday, reaching $2.25. 152,458 shares of the company's stock traded hands, compared to its average volume of 318,862. The firm's 50 day simple moving average is $2.16 and its 200-day simple moving average is $1.87. ProQR Therapeutics N.V. has a 12 month low of $1.07 and a 12 month high of $4.62.
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). The business had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. As a group, equities analysts forecast that ProQR Therapeutics N.V. will post -0.31 earnings per share for the current fiscal year.
ProQR Therapeutics Company Profile
(
Free Report)
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
Featured Articles
Before you consider ProQR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.
While ProQR Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access